Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 2/20 | 0.55 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2371436 | 1.00 | GRIN2B (0.55) | GRIN2BMIFLDHAIDO1SMN1; SMN2 | |
| SCHEMBL15000004 | 0.81 | GRIN2B (0.54) | GRIN2BMIFIDO1SMN1; SMN2ALDH1A1 | |
| SCHEMBL15000001 | 0.81 | GRIN2B (0.54) | GRIN2BMIFIDO1SMN1; SMN2ALDH1A1 | |
| SCHEMBL9880047 | 0.80 | MIF (0.53) | GRIN2BMIFLDHAIDO1SMN1; SMN2 | |
| SCHEMBL931264 | 0.78 | NOS2 (0.55) | GRIN2BSMN1; SMN2ALDH1A1 | |
| SCHEMBL17113641 | 0.78 | NOS2 (0.55) | GRIN2BSMN1; SMN2ALDH1A1 | |
| SCHEMBL8355436 | 0.78 | NOS2 (0.55) | GRIN2BSMN1; SMN2ALDH1A1 | |
| SCHEMBL4093147 | 0.74 | GRIN2B (0.65) | GRIN2BMIFIDO1ALDH1A1 | |
| SCHEMBL19149163 | 0.73 | NOS3 (0.60) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL20657405 | 0.73 | NOS3 (0.60) | SMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-20240058315-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | NOVARTIS AG (CH) | 2024-02-22 | — | — | US | disclosed |
| EP-3980121-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF, COPD, AND BRONCHIECTASIS | Novartis AG (CH) | 2022-04-13 | — | — | EP | disclosed |
| US-20210228554-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG (CH) | 2021-07-29 | — | — | US | disclosed |
| WO-2020250116-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF, COPD, AND BRONCHIECTASIS | NOVARTIS AG (CH) | 2020-12-17 | — | — | WO | disclosed |
| US-20200383960-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | NOVARTIS AG (CH) | 2020-12-10 | — | — | US | disclosed |
| US-20190262324-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG (CH) | 2019-08-29 | — | — | US | disclosed |
| US-10117858-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2018-11-06 | — | — | US | disclosed |
| US-RE46757-E1 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2018-03-20 | — | — | US | disclosed |
| US-20170071919-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| US-9365552-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2016-06-14 | — | — | US | disclosed |
| EP-2547656-B1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | NOVARTIS AG (CH) | 2015-09-30 | — | — | EP | disclosed |
| EP-2845593-A1 | Pyridine and pyrazine derivative for the treatment of chronic obstructive pulmonary disease | Novartis AG (CH) | 2015-03-11 | — | — | EP | disclosed |
| US-20150045364-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG (CH) | 2015-02-12 | — | — | US | disclosed |
| US-20140135329-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | BAETTIG URS (GB) | 2014-05-15 | — | — | US | disclosed |
| US-8476269-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-20120277232-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG | 2012-11-01 | — | — | US | disclosed |
| US-8247436-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2012-08-21 | — | — | US | disclosed |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228554-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | GRIN2B 2756/4885MIF 3092/4885LDHA 4491/4885 |
| US-20200383960-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | CFTR, OPRK1, CHRM3 | GRIN2B 3474/4885MIF 3197/4885LDHA 4072/4885 |
| US-10117858-B2 | Pyridine and pyrazine derivative for the treatment of CF | CFTR, OPRK1, OPRD1 | GRIN2B 2756/4885MIF 3092/4885LDHA 4491/4885 |
| US-20190262324-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | GRIN2B 2756/4885MIF 3092/4885LDHA 4491/4885 |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | GRIN2B 2756/4885MIF 3092/4885LDHA 4491/4885 |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | CFTR, OPRK1, CHRM3 | GRIN2B 2493/4885MIF 3032/4885LDHA 4299/4885 |
| US-20240058315-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | CFTR, OPRK1, CHRM3 | GRIN2B 3474/4885MIF 3197/4885LDHA 4072/4885 |
| US-20120277232-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | GRIN2B 2756/4885MIF 3092/4885LDHA 4491/4885 |
| US-20170071919-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | GRIN2B 2756/4885MIF 3092/4885LDHA 4491/4885 |
| US-20150045364-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | GRIN2B 2756/4885MIF 3092/4885LDHA 4491/4885 |
| US-20140135329-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | GRIN2B 2756/4885MIF 3092/4885LDHA 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.